Contraception and gynaecological care

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 23, Issue 2, 2009, Pages 211-220

  Cameron, Sharon ^a,b  

^a Family Planning and well women services ^*  (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

gynaecology; hormonal contraception; intra uterine system; non contraceptive benefits; oral contraceptive pill

Indexed keywords

CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DANAZOL; DESOGESTREL; DROSPIRENONE; ETHINYLESTRADIOL; ETONOGESTREL; FINASTERIDE; GESTAGEN; GESTODENE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN DERIVATIVE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; NAPROXEN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; SPIRONOLACTONE; TAMOXIFEN; CONTRACEPTIVE AGENT;

ACNE; ADJUVANT THERAPY; AMENORRHEA; ARTICLE; BONE DENSITY; BREAST CANCER; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; DYSMENORRHEA; EARLY MENOPAUSE; ENDOMETRIOSIS; ENDOMETRIUM ABLATION; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; EVIDENCE BASED PRACTICE; FERTILIZATION IN VITRO; GYNECOLOGIC CARE; GYNECOLOGIC DISEASE; HIRSUTISM; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; LOW DRUG DOSE; MENOPAUSE; MENORRHAGIA; MENSTRUATION DISORDER; OUTCOME ASSESSMENT; OVARY CANCER; OVARY CYST; PELVIS PAIN SYNDROME; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; UTERUS MYOMA; CONFIDENCE INTERVAL; ENDOMETRITIS; FEMALE; UTERINE NEOPLASMS; WOMEN'S HEALTH;

CONFIDENCE INTERVALS; CONTRACEPTIVE AGENTS, FEMALE; DYSMENORRHEA; ENDOMETRITIS; FEMALE; HIRSUTISM; HUMANS; UTERINE NEOPLASMS; WOMEN'S HEALTH;

EID: 60949087571     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2008.11.003     Document Type: Article

References (67)

1. Registrations of cancer diagnosed in England 2005. Available from:. www.statistics.gov.uk/downloads/theme_health/MB1_36/MB1_No36_2005.pdf [last accessed 09.11.08]
2. Hannaford P.C., Selvaraj S., Elliott A.M., et al. Cancer risk among users of ral contraceptives: cohort data from the Royal College of General Practitioners oral contraception study. BMJ 335 (2007) 651
3. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 371 (2008) 303-314
4. Wiederpass E., Adani H., Baron J.A., et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 10 (1999) 277-284
5. Vessey M., and Painter R. Oral contraceptive use and cancer: findings in a large cohort 1968-2004. Br J Cancer 95 (2006) 385-389
6. Wildermeersch D., and Dhont M. Treatment of non atypical, endometrial hyperplasia with a levonorgestrel intrauterine system. Am J Obstet Gynecol 188 (2003) 1297-1298
7. Rose G.L., and Edmonds D.K. Levonorgestrel IUS - treatment for endometrial cystic hyperplasia. J Obstet Gynecol 2 (2001) 642-643
8. Flemming R., Sathiyathasan S., and Jackson A. Endometrioid adenocarcinoma after insertion of a levonorgestrel-releasing intrauterine system. J Minim Invasive Gynecol 15 (2008) 771-773
9. Dunlop M.G., Farrington S.M., Carothers A.D., et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6 (1997) 105-110
10. Hubacher D., and Grimes D.A. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 57 (2002) 120-128
11. Chan S.S., Tam W.H., Yeo W., et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. Br J Obstet Gynaecol 114 (2007) 1510-1515
12. Gardner F.J., Konje J.C., Abrams K.R., et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 356 (2000) 1711-1717
13. Trinh X.B., Tjalma W.A., Makar A.P., et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 90 (2008) 17-22
14. World Health Organization. Medical eligibility criteria for contraceptive use. Available from:. www.who.int/reproductive-health/publications/mec/ [last accessed 09.11.08]
15. UK medical eligibility criteria for contraceptive use 2005/2006. Available from:. www. ffprhc. org. uk/admin/uploads/298_UKMEC_2005/2006. pdf
16. Vessey M., Metcalfe A., Wells C., et al. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. BMJ 294 (1987) 1518-1520
17. Booth M., Beral V., Maconochi N., et al. A case-control study of benign ovarian tumours. J Epidemiol Commun Health 46 (1992) 528-531
18. Holt V.L., Daling J.R., McNight B., et al. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol 79 (1992) 529-533
19. Lanes S.F., Birmann B., Walker A.M., et al. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 166 (1992) 956-961
20. Teichmann A.T., Brill K., Albring M., et al. The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth. Gynecol Endocrinol 9 (1995) 299-305
21. Steinkampf M.P., Hammond K.R., and Blackwell R.E. Hormonal treatment of functional ovarian cysts: a randomized, prospective study. Fertil Steril 54 (1990) 775-777
22. Turan C., Zorlu C.G., Ugur M., et al. Expectant management of functional ovarian cysts: an alternative to hormonal therapy. Int J Gynaecol Obstet 47 (1994) 257-260
23. Stewart A., Cummins C., Gold L., et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol 108 (2001) 74-86
24. Reid P.C., and Mukri F. Trends in number of hysterectomies performed in England for menorrhagia: examination of health episode statistics, 1989 to 2002-3. BMJ 330 (2005) 938-939
25. Lethaby A.E., Cooke I., and Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 19 (2005) CD002126
26. Hurskainen R., Teperi J., Rissanen P., et al. Clinical outcomes and costs with levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 291 (2004) 1456-1463
27. National Institute for Health and Clinical Excellence. Heavy menstrual bleeding. Available from: (2007). www.nice.org.uk/nicemedia/pdf/CG44FullGuideline.pdf [last accessed 09.11.08]
28. Larsson G., Milson I., Lydstedt G., et al. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 46 (1992) 327-334
29. Fraser I.S., and McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 31 (1991) 66-70
30. Archer D.F., Jensen J.T., Johnson J.V., et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 74 (2006) 439-445
31. National Institute for Health and Clinical Excellence. Long acting reversible contraception. Available from: (2005). www.nice.org.uk/nicemedia/pdf/CG030fullguideline.pdf
32. Mercorio F., De Simone R., Sardo A.D., et al. The effect of levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception 67 (2003) 277-280
33. Grigorevia V., Chen-Mok M., Tarasova M., et al. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 79 (2003) 1194-1198
34. Singer A., and Ikomi A. Successful treatment of fibroids using an intrauterine progesterone device. Int J Gynaecol Obstet 46 (1994) 55
35. Fong Y.F., and Singh K. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient. Contraception 60 (1999) 51-53
36. Magalhaes J., Aldrighi J.M., and de Lima G.R. Uterine volume and menstrual patterns in users of the levonorgestrel releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception 75 (2007) 193-198
37. Maruo T., Matsuo H., Samoto T., et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 65 (2000) 585-592
38. Ross K.K., Pike M.C., Vessey M.P., et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ 293 (1986) 1027
39. Venkatachalam S., Bagratee J.S., and Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynecol 24 (2004) 798-800
40. Lockhat F.B., Emembolu J.O., and Konje J.E. The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum Reprod 19 (2004) 179-184
41. Abbou-Setta A.M., Al Inany H.G., and Farquhar C.M. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst Rev 4 (2006) CD005072
42. Bahamondes L., Petta C.A., Fernandes A., et al. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception 75 Suppl. (2007) S134-S139
43. Gomes M., Ferriani R., Rose e Silva J.C., et al. The levonorgestrel-releasing intrauterine system and endometriosis staging. Fertil Steril 87 (2007) 1231-1234
44. Lockhat F.B., Emembolu J.O., and Konje J.E. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 20 (2005) 789-793
45. Davis L., Kennedy S.S., Moore J., et al. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 3 (2007) CD001019
46. Vercellini P., Frontino G., De Giorgi O., et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 80 (2003) 560-563
47. Vercellini P., De Giorgi O., Oldani S., et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 175 (1996) 396-401
48. Jain J., Jakimiuk A.J., Bode F.R., et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 70 (2004) 269-275
49. Crosignani P.G., Luciano A., Ray A., et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 21 (2006) 248-256
50. Schlaff W.D., Carson S.A., Luciano A., et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 85 (2006) 314-325
51. Razzi S., Luisi S., Ferretti C., et al. Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol 135 (2007) 188-190
52. Yisa S.B., Okenwa A.A., and Husemeyer R.P. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plann Reprod Healthcare 31 (2005) 67-70
53. Hughes E., Brown J., Collins J.J., et al. Ovulation suppression for endometriosis. Cochrane Database Syst Rev 18 (2007) CD000155
54. Arowojolu A.O., Gallo M.F., Lopez L.M., et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 24 (2007) CD004425
55. Batukan C., Muderis II, Ozcelik B., et al. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 23 (2007) 38-44
56. Christensen J.T., Boldsoen J., and Westergaard J.G. Ovarian volume in gynecologically healthy women using contraception or using IUD. Acta Obstet Gynecol Scand 76 (1997) 784-789
57. Rotterdam/ESHRE-ASHRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004) 41-47
58. Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome. Green-top guideline no. 48. Available from: (2007), RCOG, London. www.rcog.org.uk/resources/public/pdf/green_top48_pms.pdf [last accessed 05.11.08]
59. Graham C.A., and Sherwin B.B. A prospective treatment study of pre-menstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 36 (1992) 257-266
60. Lopez L.M., Kaptein A., and Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 23 (2008) CD006586
61. Wildemeersch D., Pylyser K., De Wever N., et al. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution. Maturitas 57 (2007) 205-209
62. Beral V., Reeves G., and Banks E. Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. Br J Obstet Gynaecol 112 (2005) 692-695
63. Kuohung W., Borgatta L., and Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 61 (2000) 77-82
64. Templeton A., Van Look P., Lumsden M.A., et al. The recovery of pre-ovulatory oocytes using a fixed schedule of ovulation induction and follicle aspiration. Br J Obstet Gynaecol 91 (1984) 148-154
65. Biljan M.M., Mahutte N.G., Dean N., et al. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertil Steril 70 (1998) 1063-1069
66. al-Mizyen E., Sabatini L., Lower A.M., et al. Does pretreatment with progestogen or oral contraceptive pills in low responders followed by the GnRHa flare protocol improve the outcome of IVF-ET?. J Assist Reprod Genet 17 (2000) 140-146
67. Greisinger G., Venetis C.A., Marx T., et al. Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil Steril 90 (2008) 1055-1063